anxiety
ANXIETY

Anxiety disorders are disorders wherein the patient experiences uncontrollable fear or anxiety with behavioral disturbances that affects normal functioning.

Generalized anxiety disorder is having excessive anxiety and worry occurring for at least 6 months about several events or activities. The person finds it difficult to control the worry.
Panic disorder is when the person experienced recurrent unexpected panic attacks.
Social anxiety disorder is marked and persistent fear of social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others.

Drug Information

Indication: Major depressive episode, panic disorder w/ or w/o agoraphobia, social or generalized anxiety disorder, obsess...

Indication: Neuropathic pain in adults. Adjunctive therapy in adults w/ partial seizures w/ or w/o secondary generalisatio...

Indication: Depressive syndromes.

Indication: Symptomatic treatment of depression including depression accompanied by symptoms of anxiety in patients w/ or ...

Indication: Short-term treatment of moderate or severe anxiety & anxiety associated w/ depression.

Dosage: Anxiety Initially 0.25-0.5 mg tds. Usual dose range: 0.5-4 mg daily. Depression Initially 0.5 mg tds. Usual do

Indication: Symptomatic treatment of depression including depression accompanied by symptoms of anxiety. Obsessive compuls...

Indication: Depression & prevention of relapse/recurrence; panic disorder (PD) w/ or w/o agoraphobia; obsessive-compul...

Indication: Major depressive disorder, generalized anxiety disorder. Management of diabetic peripheral neuropathic pain.

Indication: Anxiety, acute alcohol w/drawal symptoms, pre-op procedures to relieve anxiety & tension; adjunct prior to...

1  /  8
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.